tbuckley/cabot-search huggingface dataset:
Intestinal Microbiota Composition Is Associated with Minimal Residual Disease Negativity in Patients with Multiple Myeloma
Authors: Matthew J. Pianko, Sean M Devlin, Eric R. Littmann, Aisara Chansakul, Donna Mastey, Meghan Salcedo, Emily Fontana, Lilan Ling, Elizabet Tavitian, John B. Slingerland, Ann E. Slingerland, Annelie Clurman, Antonio LC Gomes, Ying Taur, Eric G. Pamer, Jonathan U. Peled, Marcel R.M. van den Brink, Ola Landgren, Alexander M. Lesokhin
Journal: Blood (2018)
WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)
Authors: Brett M Stevens, Amanda Winters, Taher Abbasi, Neeraj Kumar Singh, Yashaswini S Ullal, Ilu Kumari, Anuj Tyagi, Aftab Alam, Neelesh Lunkad, Leylah M. Drusbosky, Christopher R. Cogle, Shireen Vali, Daniel A Pollyea
Journal: Blood (2018)
Harder to Treat Than Leukemia — Opioid Use Disorder in Survivors of Cancer
Authors: Alison Wakoff Loren
Journal: New England Journal of Medicine (2018)

Interview with Dr. Alison Loren on the risk of opioid use disorder in survivors of cancer and judicious prescribing of pain medications. (07:42)Download Woven into our language about the opioid epidemic is an implication that oncologists can hand out opioids as if there were no tomorrow. But for many people with cancer, there is now indeed a tomorrow — one that should be free of opioid addiction.
Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
Authors: Shaji K. Kumar, Prashant Kapoor, Betsy Laplant, Eli Muchtar, Francis K. Buadi, Wilson I Gonsalves, David Dingli, Ronald S. Go, Rahma Warsame, Taxiarchis Kourelis, John A. Lust, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman, Yi Hwa, Amie Fonder, Miriam Hobbs, Nelson Leung, S. Vincent Rajkumar, Morie A. Gertz, Eric Wolfe
Journal: Blood (2018)
Abstract P072: Early Response Predicts One-Year Weight-Reduction Goal Achievement with MOVE!®
Authors: Jane Garvin, Karen Cota
Journal: Circulation (2016)

Introduction: Previous reports suggested that age, gender, race, and participation predicted weight reduction in the weight-reduction program, MOVE!®, available at Veterans Administration Medical Centers. It is not known if early response to the MOVE!® program predicts continued participation or weight reduction. Hypothesis: We assessed the hypothesis that early weight reduction success with MOVE!® would predict ongoing participation and weight-reduction goal achievement at one year. Methods: Using longitudinal clinical data from electronic health records of 107 MOVE!® program participants with 1-month and 1-year data, MOVE!® sessions and weight reduction were examined in this secondary analysis. Participation was based on group session attendance. Attending 14 or more sessions within the first 6 months was selected as a participation cut point based on the 2013 guidelines for overweight and obesity management. Early response was based on at least 1% weight reduction from baseline at week four. Weight-reduction success at one year was based on at least 5% reduction from baseline. Results: Participants were 59.3 (SD=11.1, SEM=1.1) years of age on average; female 13% (14 of 107); African American 54% (58 of 107); Caucasian 46% (49 of 107); with a mean BMI of 35.5(SD=5.0, SEM=0.49) and attended 7.3 (SD=4.9 , SEM=0.5) sessions on average. Total 6-month group session participation was not explained by early weight reduction success (t = 0.81; CI -1.11, 2.63; p = .42). Early responders were no more likely to participate in 14 or more MOVE!® sessions within 6 months than participants who were not early responders (OR = 1.2; CI 0.34, 4.20; p = .78). Early responders were seven times as likely to achieve at least the 5% weight reduction goal at one year compared to those participants who were not early responders, while controlling for age, gender, race, and total group sessions (OR = 6.96; CI 1.85, 26.13; p = .004). Conclusions: Early response was a significant predictor of at least 5% weight reduction goal achievement at one year. However, early response was not a predictor of participation or ongoing participation reaching 14 sessions in 6 months. Further study is needed to determine genetics as well as other predictors of early response to MOVE!®.
Abstract 19306: Predictors of Mortality in Patients Admitted With Spontaneous Coronary Artery Dissection
Authors: Shubha Deep Roy, Siva Sagar Taduru, Anweshan Samanta, Dushyant Ramakrishnan, Paramdeep Baweja
Journal: Circulation (2017)

Introduction: Spontaneous coronary artery dissection (SCAD) is a rare clinical entity and not much is known about the factors associated with mortality in these patients. Objective: Our aim was to find the factors associated with mortality in patients presenting with SCAD. Methods: We searched the National Inpatient Sample (NIS) from 2008 to 2014 using International Classification of Diseases (ICD-9-CM) codes for patients with primary diagnosis of SCAD (414.12). We also identified patients who underwent percutaneous coronary intervention (PCI) using ICD 9 codes (00.66, 36.06, 36.07). We used chi-square test and ANOVA to compare categorical and continuous variables respectively. We performed multivariate binary logistic regression to identify adjusted odds-ratio (AOR) for in-hospital all-cause mortality. We performed multivariate linear regression to identify factors associated with differences in length of stay (LOS). Results: We identified a total of 1,513 (weighted) patients admitted with the primary di...
Tax foods high in sugar and salt to improve nation’s health, CMO urges
Authors: Gareth Iacobucci
Journal: BMJ (2018)

The UK government should widen the current tax on sugary drinks to cover a range of foods that are high in sugar, salt, and trans fats to help tackle preventable disease, England’s chief medical officer has advised.

Ministers should also extend the existing tax, called the soft drinks industry levy, to sweetened milk based drinks and impose an outright ban on added salt and sugar in baby foods, Sally Davies said in her annual report.1

The report sets out her ambition to create a healthier England by 2040. A key …
Abstract 20877: A Scaffold-Free 3D Spheroid Model Derived From hiPSC-Differentiated Cardiomyocytes for Myocardial Infarction Therapy Applications
Authors: Saidulu Mattapally, Wuqiang Zhu, Vladimir G Fast, Chelsea Worley, Ling Gao, Ramaswamy Kannappan, Jianyi Zhang
Journal: Circulation (2017)

Introduction: Human induced pluripotent stem cells (hiPSCs) hold enormous potential for cell-based therapy applications as they are capable of giving rise to unlimited number of terminally differen...
Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis
Authors: Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Alessandra Iurlo, Mariella D'Adda, Fabio Stagno, Luciano Levato, Bruno Martino, Francesca Lunghi, Mario Tiribelli, Giovanna Rege Cambrin, Elisabetta Abruzzese, Serena Rupoli, Antonella Gozzini, Patrizia Pregno, Marzia Salvucci, Elena Trabacchi, Giovanni Caocci, Anna Rita Scortechini, Luigia Luciano, Giuseppe Tagariello, Massimiliano Bonifacio, Simona Soverini, Robin Foà, Giovanni Martinelli, Michele Cavo, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti
Journal: Blood (2018)
T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes
Authors: Scott R Solomon, Andrew St. Martin, Nirav N Shah, Giancarlo Fatobene, Monzr Al Malki, Karen K. Ballen, Asad Bashey, Nelli Bejanyan, Javier Bolaños-Meade, Claudio G Brunstein, Zachariah Defilipp, Richard E Champlin, Ephraim J. Fuchs, Mehdi Hamadani, Peiman Hematti, Christopher G. Kanakry, Joseph P. McGuirk, Ian K. McNiece, Stefan O. Ciurea, Marcelo C. Pasquini, Vanderson Rocha, Rizwan Romee, Sagar S. Patel, Sumithira Vasu, Edmund K. Waller, John R. Wingard, Mei-Jie Zhang, Mary Eapen
Journal: Blood (2018)
Comment on Cheung and Moses. Gestational Diabetes Mellitus: Is It Time to Reconsider the Diagnostic Criteria? Diabetes Care 2018;41:1337–1338
Authors: David A. Sacks
Journal: Diabetes Care (2018)

While it may be unconventional to comment on a Commentary, emphasis on some of the points raised by Cheung and Moses (1) as well as the addition of a few others seems indicated. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study, which combined data from 15 medical centers on five continents, created a large database of glucose tolerance test (GTT) results of pregnant women representing a diversity of racial and ethnic groups. Their combined data demonstrated a near-linear positive association between maternal glucose levels and selected adverse pregnancy outcomes (2). Given this observation, one may reasonably infer that threshold values defining gestational diabetes mellitus (GDM) derived from these data will correctly identify for …
Organic selenium synergizes with tamoxifen to induce apoptosis in breast cancer cells and inhibit tamoxifen-sensitive and -resistant breast cancer xenografts
Authors: Zengshan Li, Latonya Carrier, Virgilio Salvo, Matthew Burow, Brian Rowan
Journal: Cancer Research (2007)

4293  Tamoxifen is widely prescribed as hormonal therapy for breast cancer and as a chemopreventative. Tamoxifen binds to estrogen receptor (ER) and antagonizes estrogen-mediated breast cancer growth. Despite the benefits of tamoxifen, almost all tamoxifen-responsive patients develop resistance to therapy. Selenium is an essential micronutrient currently in clinical trials for cancer prevention. Recent evidence now demonstrates the potential of utilizing selenium in a new way: as a novel therapy for overt cancer through combination with well-established chemotherapeutic and hormonal agents. We previously showed that organic selenium disrupts ERα signaling via downregulation of ERα and that selenium potentiates tamoxifen efficacy in tamoxifen-sensitive breast cancer cells and restored tamoxifen sensitivity in tamoxifen-resistant cells. The present work extends these studies to examine the effects of selenium + tamoxifen on apoptosis and growth of human breast cancer xenografts. Methylseleninic acid (MSA, 10 μM), a nontoxic, monomethylated form of selenium, but not 4-hydroxytamoxifen (10-7M), induced apoptosis of tamoxifen-sensitive MCF-7 cells and -resistant MCF-7-LCC2 cells in vitro as measured by quantitation of histone-associated DNA fragments. Remarkably, addition of tamoxifen to MSA resulted in synergistic apoptosis in both cell lines. In both MCF7 and MCF7-LCC2 cells, MSA and MSA + tamoxifen activated Bim, cytochrome-C, PARP, and caspases 7, 8, 9 but not caspases 2, 6, 10, 12 as measured by Western blot. Inhibitors of caspase 8 (Z-IETD-FMK, 20 μM) and 9 (Z-LEHD-FMK, 20 μM) blocked MSA + tamoxifen induced apoptosis. These data support a model in which MSA or MSA + tamoxifen activate the intrinsic, mitochondrial apoptotic pathway with cross-talk to caspase 8.  Methylselenocysteine (MSC) was used in in vivo studies for reasons of efficacy, lack of toxicity, and recent approval for human clinical trials. 5 x 106 MCF-7 cells were bilaterally injected into mammary fat pads of ovariectomized nu/nu mice and implanted with an estradiol pellet (0.72 mg) until palpable tumor (10 days). At day 10, administration of either MSC (100 μg/mouse/day IP) or tamoxifen (5 mg implant) for an additional 30 days did not significantly alter estrogen-stimulated tumor growth. However, co-administration of MSC with tamoxifen completely suppressed growth of MCF-7 tumors.  These data indicate that elevated apoptosis may underlie synergistic growth inhibition of breast cancer by combination of organic selenium with tamoxifen. Combination of selenium with tamoxifen may delay the onset of tamoxifen resistance while simultaneously improving therapeutic efficacy.
Financial Compensation For Hepatologists in Different Practice Settings
Authors: Mitchell L. Shiffman, Norman L. Sussman, Natarajan Ravendhran, Macia Ditmyer, Kris V. Kowdley, Marcelo Kugelmas
Journal: Hepatology (2018)

Several governmental agencies and private organizations monitor data on relative value units (RVUs) and salary earned by various medical specialists. There are currently no data that define the RVU production and salary earned by hepatologists. A web-based survey that queried the number of patients that a hepatologist cares for, RVU production, and salary support was sent to 2,587 members of the American Association for the Study of Liver Diseases. A total of 391 members completed the survey, 229 of whom reported spending more than 75% of their time in clinical practice/direct patient care and served as the basis for this analysis. The mean age of the cohort was 48 years, 77% were male, and all regions of country were represented. Their mean duration in clinical practice was 11.4 years. Hepatologists worked in four practice settings: university hospital with a liver transplant (LT) program (UHLT, n = 148), non-university hospital with LT (nonUHLT, n = 35), university hospital with no LT (UHnoLT, n = 29), and community practice (CP, n = 17). The average number of patients seen monthly was lowest for hepatologists at a UHLT (154) and highest for those in CP (293). Hepatologists at LT programs saw the highest percentage of patients with liver disease (91% of encounters), performed the fewest endoscopic procedures (12%-17%), but received the highest compensation/RVU ($68-$85) compared with hepatologists at UHnoLT and CP ($44-$63/RVU). The mean base salary for all hepatologists with fewer than 5 years of experience was $273,507, and this increased to $347,656 for those with more than 5 years of experience. We concluded that hepatologists at LT centers are compensated at much higher rates per encounter than in other practice settings. This may be due to salary subsidies provided by the UHLT and nonUHLT to their hepatologists.
Targeting carbon nanotubes based on IGF-1R for photothermal therapy of orthotopic pancreatic cancer guided by optical imaging
Authors: Guan-Hua Lu, Wen-Ting Shang, Han Deng, Zi-Yu Han, Min Hu, Xiao-Yuan Liang, Chi-Hua Fang, Xin-Hong Zhu, Ying-Fang Fan, Jie Tian
Journal: Biomaterials (2018)
Simple stool processing method for the diagnosis of pulmonary tuberculosis using GeneXpert MTB/RIF
Authors: Basti Andriyoko, Harini Janiar, Retno Kusumadewi, Eveline Klinkenberg, Petra de Haas, Edine Tiemersma
Journal: European Respiratory Journal (2018)

<b>A simple processing method for stool with Xpert MTB/RIF yields reliable results for young children, thus providing opportunity for painless bacteriological diagnosis of TB in children at the lowest healthcare levels.</b>http://ow.ly/8CEI30nb0He
Jaw Clonus and Limb Fasciculations
Authors: Ankur Wadhwa, Atri Chatterjee
Journal: New England Journal of Medicine (2018)

A 24-year-old man presented with progressive dysphagia, dysarthria, and weakness in his arms and legs. The physical examination showed jaw clonus and muscle fasciculations (shown in a video), consistent with a diagnosis of amyotrophic lateral sclerosis.
TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Authors: M. Lia Palomba, Jacob Garcia, Lei Wang, Christine Dehner, Karen C. Chung, David G. Maloney
Journal: Blood (2018)
Nitroimidazole Resistance in <i>Trichomonas vaginalis</i> Infection
Authors: Antonio Salas, Matthew M. Hamill, Susan Tuddenham
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Hypermethylation of <i>SHISA3</i> Promotes Nasopharyngeal Carcinoma Metastasis by Reducing SGSM1 Stability
Authors: Jian Zhang, Ying-Qin Li, Rui Guo, Ya-Qin Wang, Pan-Pan Zhang, Xin-Ran Tang, Xin Wen, Xiao-Hong Hong, Yuan Lei, Qing-Mei He, Xiao-Jing Yang, Ying Sun, Jun Ma, Na Liu
Journal: Cancer Research (2018)

Abstract Altered DNA methylation is a key feature of cancer, and aberrant methylation is important in nasopharyngeal carcinoma (NPC) development. However, the methylation mechanisms underlying metastasis of NPC remain unclear. Analyzing data from public databases and conducting our own experiments, we report here that promoter hypermethylation of SHISA3 is common and contributes to the downregulation of this gene in many types of tumors, including NPC. SHISA3 suppressed NPC cell invasion and metastasis in vitro and in vivo by impeding the E3 ubiquitin ligase tripartite motif containing 21 (TRIM21)–mediated ubiquitination and degradation small G protein signaling modulator 1 (SGSM1) and by inhibiting the MAPK pathway activation. Silencing SGSM1 abrogated the inhibitory effect of SHISA3 on NPC cell migration and invasion. This newly identified SHISA3–TRIM21–SGSM1 axis could be a novel therapeutic target in NPC. Significance: These findings highlight the mechanism by which a newly identified tumor suppressor SHISA3 suppresses invasion and metastasis of nasopharyngeal carcinoma.
Hematopoietic Cell Transplantation in First Remission Amongst Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Level Analysis across the United States
Authors: Lori S Muffly, Qian Li, Elysia Alvarez, Justine M. Kahn, Lena E. Winestone, Rosemary Cress, Dolly Penn, Theresa H.M. Keegan
Journal: Blood (2018)
Abstract 16939: Association of Change in BMI From Early Adulthood to Middle Age With Left Atrial Structure and Function by Three-dimension Speckle Tracking Echocardiography: The Coronary Artery Risk Development in Young Adults (CARDIA) Study
Authors: Henrique Doria de Vasconcellos, Aisha S Betoko, Luisa Ciuffo, Bharat Ambale-Venkatesh, Henrique T Moreira, Jared P Reis, Norrina Allen, Donald Lloyd-Jones, Laura Colangelo, Pamela Schreiner, Cora E Lewis, Stephen Sidney, Christopher Cox, Samuel S Gidding, Joao A Lima
Journal: Circulation (2017)

Background: Longstanding obesity is associated with impaired left ventricle (LV) systolic and diastolic function evaluated by two-dimension echocardiography. Left atrial (LA) remodeling is a progno...
Abstract 14979: Progressive Heart Failure is Uncommon in Patients With Nonobstructive Hypertrophic Cardiomyopathy
Authors: Ethan J Rowin, Barry J Maron, Iacopo Olivotto, Susan A Casey, Anna Arretini, Benedetta Tomberli, Ross Garberich, Mark S Link, Raymond H Chan, Evan Appelbaum, John R Lesser, James E Udelson, Martin S Maron
Journal: Circulation (2013)

Background: Historically, left ventricular outflow tract obstruction has been the most visible pathophysiologic component of HCM, with substantial attention directed toward its management strategie...
Long noncoding RNA NEXN-AS1 mitigates atherosclerosis by regulating the actin-binding protein NEXN
Authors: Yan-Wei Hu, Feng-Xia Guo, Yuan-Jun Xu, Pan Li, Zhi-Feng Lu, David G. McVey, Lei Zheng, Qian Wang, John H. Ye, Chun-Min Kang, Shao-Guo Wu, Jing-Jing Zhao, Xin Ma, Zhen Yang, Fu-Chun Fang, Yu-Rong Qiu, Bang-Ming Xu, Lei Xiao, Qian Wu, Li-Mei Wu, Li Ding, Tom R. Webb, Nilesh J. Samani, Shu Ye
Journal: Journal of Clinical Investigation (2018)

Noncoding RNAs are emerging as important players in gene regulation and disease pathogeneses. Here, we show that a previously uncharacterized long noncoding RNA, nexilin F-actin binding protein antisense RNA 1 (NEXN-AS1), modulates the expression of the actin-binding protein NEXN and that NEXN exerts a protective role against atherosclerosis. An expression microarray analysis showed that the expression of both NEXN-AS1 and NEXN was reduced in human atherosclerotic plaques. In vitro experiments revealed that NEXN-AS1 interacted with the chromatin remodeler BAZ1A and the 5' flanking region of the NEXN gene and that it also upregulated NEXN expression. Augmentation of NEXN-AS1 expression inhibited TLR4 oligomerization and NF-κB activity, downregulated the expression of adhesion molecules and inflammatory cytokines by endothelial cells, and suppressed monocyte adhesion to endothelial cells. These inhibitory effects of NEXN-AS1 were abolished by knockdown of NEXN. In vivo experiments using ApoE-knockout mice fed a Western high-fat diet demonstrated that NEXN deficiency promoted atherosclerosis and increased macrophage abundance in atherosclerotic lesions, with heightened expression of adhesion molecules and inflammatory cytokines, whereas augmented NEXN expression deterred atherosclerosis. Patients with coronary artery disease were found to have lower blood NEXN levels than healthy individuals. These results indicate that NEXN-AS1 and NEXN represent potential therapeutic targets in atherosclerosis-related diseases.
Toxicogenomics: A 2020 Vision
Authors: Zhichao Liu, Ruili Huang, Ruth Roberts, Weida Tong
Journal: Trends in Pharmacological Sciences (2018)

HighlightsTogether with the promotion of non-animal testing, in vitro toxicogenomics (TGx) may play a vital role in the next-generation risk assessment paradigm.A strategic shift in risk assessment provides an unprecedented opportunity for repositioning TGx in the regulatory setting.As the emerging technique continues to impact the TGx field, novel genomic features such as miRNAs, ncRNAs, and circular RNAs may provide more resolution towards better understanding of the underlying mechanisms of toxicological processes.Advances in machine learning and artificial intelligence are gaining ground for their applicability in biomedical fields. In the near future, these advances may be further applied in the TGx field to improve predictive power.AbstractToxicogenomics (TGx) has contributed significantly to toxicology and now has great potential to support moves towards animal-free approaches in regulatory decision making. Here, we discuss in vitro TGx systems and their potential impact on risk assessment. We raise awareness of the rapid advancement of genomics technologies, which generates novel genomics features essential for enhanced risk assessment. We specifically emphasize the importance of reproducibility in utilizing TGx in the regulatory setting. We also highlight the role of machine learning (particularly deep learning) in developing TGx-based predictive models. Lastly, we touch on the topics of how TGx approaches could facilitate adverse outcome pathways (AOP) development and enhance read-across strategies to further regulatory application. Finally, we summarize current efforts to develop TGx for risk assessment and set out remaining challenges.
A prospective, clinical, nonrandomized controlled trial of individualized, nurse‐led patient‐centred intervention in patients with psoriasis
Authors: L.R. Khoury, T. Møller, C. Zachariae, H. Correll, N.B. Jørgensen, C. Pedersen, M. Pors, C. Bundy, L. Skov
Journal: British Journal of Dermatology (2018)